Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study Academic Article uri icon

Overview

MeSH Major

  • Crohn Disease
  • Escherichia coli
  • Gram-Positive Bacteria
  • Ileum
  • Intestinal Mucosa

abstract

  • Certolizumab pegol was effective in many patients who previously discontinued certolizumab pegol for lack or loss of response. Thus, discontinuation of therapy may not always be necessary. Safety was consistent with previous findings.

publication date

  • May 31, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4949014

Digital Object Identifier (DOI)

  • 10.1097/MIB.0000000000000805

PubMed ID

  • 27400222

Additional Document Info

start page

  • 1870

end page

  • 80

volume

  • 22

number

  • 8